Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...

Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were ...

Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company ...

Viking Therapeutics Inc. (VKTX) on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Q3 2024 Earnings Call Transcript October 23, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $71.75 which represents a decrease of $-1.60 or -2.18% from the prior close of $73.35. The stock opened at $71 and ...

Viking Therapeutics Inc.’s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form ...

Welcome to the Viking Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all parties are in a listen-only mode. Following management’s prepared remarks, there will ...

On Friday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $78.03 which represents a slight increase of $4.81 or 6.57% from the prior close of $73.22. The stock opened at ...